Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy

Journal of Gastroenterology

Volumn 46, Issue 1, 2011, Pages 9-16

  Kusumoto, Shigeru ^a   Tanaka, Yasuhito ^c   Ueda, Ryuzo ^a   Mizokami, Masashi ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Japan Konodai Hospital   (Japan)

^c NONE

Author keywords

HBV; Reactivation; Rituximab

Indexed keywords

CD20 ANTIGEN; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PREDNISOLONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; VINCRISTINE; VIRUS DNA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; GENE MUTATION; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LYMPHOCYTE DEPLETION; LYMPHOMA; NEUTROPENIA; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEROPREVALENCE; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS LOAD; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; RISK FACTORS; STEROIDS; VIRUS ACTIVATION;

EID: 78651507642     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0331-4     Document Type: Review

References (56)

1. I Dervite D Hober P Morel 2001 Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab N Engl J Med 344 68 69 1:STN:280:DC%2BD3M%2Fnt1Sgug%3D%3D 10.1056/NEJM200101043440120 11187122
2. CK Hui WW Cheung HY Zhang WY Au YH Yueng AY Leung, et al. 2006 Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy Gastroenterology 131 59 68 1:CAS:528:DC%2BD28XnvF2gsL0%3D 10.1053/j.gastro.2006.04.015 16831590
3. W Yeo TC Chan NW Leung WY Lam FK Mo MT Chu, et al. 2009 Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 605 611 1:CAS:528:DC%2BD1MXivFyju7s%3D 10.1200/JCO.2008.18.0182 19075267
4. S Kusumoto Y Tanaka M Mizokami R Ueda 2009 Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma Int J Hematol 90 13 23 1:CAS:528:DC%2BD1MXotV2qt7o%3D 10.1007/s12185-009-0359-5 19544079
5. P McLaughlin AJ Grillo-Lopez BK Link R Levy MS Czuczman ME Williams, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 2825 2833 1:CAS:528:DyaK1cXlsFCgu7c%3D 9704735
6. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 1:CAS:528:DC%2BD38XmslGgsw%3D%3D 10.1056/NEJMoa011795 11807147
7. JC Edwards L Szczepanski J Szechinski A Filipowicz-Sosnowska P Emery DR Close, et al. 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572 2581 1:CAS:528:DC%2BD2cXkvFKntrc%3D 10.1056/NEJMoa032534 15201414
8. M Scully H Cohen J Cavenagh S Benjamin R Starke S Killick, et al. 2007 Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13 Br J Haematol 136 451 461 1:CAS:528:DC%2BD2sXislShtLo%3D 10.1111/j.1365-2141.2006.06448.x 17233847
9. B Godeau R Porcher O Fain F Lefrere P Fenaux S Cheze, et al. 2008 Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study Blood 112 999 1004 1:CAS:528:DC%2BD1cXpvVOksLw%3D 10.1182/blood-2008-01- 131029 18463354
10. E Voog F Morschhauser P Solal-Celigny 2003 Neutropenia in patients treated with rituximab N Engl J Med 348 2691 2694 10.1056/NEJM200306263482620 12826650 (discussion 2691-4)
11. H Yokoyama T Watanabe D Maruyama SW Kim Y Kobayashi K Tobinai 2008 Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature Int J Hematol 88 443 447 10.1007/s12185-008-0168-2 18855101
12. JL Dienstag 2008 Hepatitis B virus infection N Engl J Med 359 1486 1500 1:CAS:528:DC%2BD1cXhtFOru7bL 10.1056/NEJMra0801644 18832247
13. B Rehermann C Ferrari C Pasquinelli FV Chisari 1996 The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response Nat Med 2 1104 1108 1:CAS:528:DyaK28Xmt1Wnu7s%3D 10.1038/nm1096-1104 8837608
14. W Yeo PK Chan S Zhong WM Ho JL Steinberg JS Tam, et al. 2000 Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors J Med Virol 62 299 307 1:CAS:528:DC%2BD3cXns1Ols7c%3D 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0 11055239
15. W Yeo B Zee S Zhong PK Chan WL Wong WM Ho, et al. 2004 Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy Br J Cancer 90 1306 1311 1:CAS:528:DC%2BD2cXis1aitL0%3D 10.1038/sj.bjc.6601699 15054446
16. GK Lau YH Leung DY Fong WY Au YL Kwong A Lie, et al. 2002 High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation Blood 99 2324 2330 1:CAS:528: DC%2BD38XisFGhsrg%3D 10.1182/blood.V99.7.2324 11895763
17. T Umemura E Tanaka K Kiyosawa H Kumada 2008 Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan Clin Infect Dis 47 e52 e56 10.1086/590968 18643758
18. Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat. 2010. doi: 10.1111/j.1365-2893.2009.01239.x.
19. AL Cheng CA Hsiung IJ Su PJ Chen MC Chang CJ Tsao, et al. 2003 Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma Hepatology 37 1320 1328 1:CAS:528: DC%2BD3sXkvFWltb4%3D 10.1053/jhep.2003.50220 12774010
20. N Dhedin C Douvin M Kuentz MF Saint Marc O Reman C Rieux, et al. 1998 Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc Transplantation 66 616 619 1:CAS:528:DyaK1cXms1Cgs7c%3D 10.1097/00007890-199809150-00012 9753342
21. A Locasciulli B Bruno EP Alessandrino G Meloni W Arcese G Bandini, et al. 2003 Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation Bone Marrow Transplant 31 295 300 1:STN:280: DC%2BD3s7gslynsQ%3D%3D 10.1038/sj.bmt.1703826 12621466
22. GK Lau R Liang EK Chiu CK Lee SK Lam 1997 Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study Bone Marrow Transplant 19 795 799 1:STN:280:DyaK2s3nvFOqtQ%3D%3D 10.1038/sj.bmt.1700744 9134171
23. P Seth AA Alrajhi I Kagevi MA Chaudhary E Colcol E Sahovic, et al. 2002 Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease Bone Marrow Transplant 30 189 194 1:STN:280:DC%2BD38vjtFyrtw%3D%3D 10.1038/sj.bmt.1703614 12189538
24. DK Wong Y Tanaka CL Lai M Mizokami J Fung MF Yuen 2007 Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection J Clin Microbiol 45 3942 3947 1:CAS:528:DC%2BD1cXntlWnug%3D%3D 10.1128/JCM.00366-07 17942661
25. N Shinkai Y Tanaka E Orito K Ito T Ohno N Hirashima, et al. 2006 Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection Hepatol Res 36 272 276 1:CAS:528:DC%2BD28Xht1ersLvN 10.1016/j.hepres.2006.08.005 16971173
26. T Yoshida S Kusumoto A Inagaki F Mori A Ito M Ri, et al. 2010 Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports Int J Hematol 91 844 849 10.1007/s12185-010-0592-y 20473594
27. F Kurbanov Y Tanaka M Mizokami 2010 Geographical and genetic diversity of the human hepatitis B virus Hepatol Res 40 14 30 10.1111/j.1872-034X.2009. 00601.x 20156297
28. Y Miyakawa M Mizokami 2003 Classifying hepatitis B virus genotypes Intervirology 46 329 338 1:CAS:528:DC%2BD3sXhtVSjt7rO 10.1159/000074988 14688448
29. Y Tanaka I Hasegawa T Kato E Orito N Hirashima SK Acharya, et al. 2004 A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D Hepatology 40 747 755 10.1002/hep.20365 15349915
30. M Omata T Ehata O Yokosuka K Hosoda M Ohto 1991 Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis N Engl J Med 324 1699 1704 1:STN:280:DyaK3M3jvV2isg%3D%3D 10.1056/ NEJM199106133242404 2034246
31. A Ozasa Y Tanaka E Orito M Sugiyama JH Kang S Hige, et al. 2006 Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection Hepatology 44 326 334 1:CAS:528:DC%2BD28XptVKmt7s%3D 10.1002/hep.21249 16871568
32. M Pfreundschuh L Trumper A Osterborg R Pettengell M Trneny K Imrie, et al. 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379 391 1:CAS:528:DC%2BD28XjvFWlsbw%3D 10.1016/S1470-2045(06) 70664-7 16648042
33. J Shortt A Spencer 2006 Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma Bone Marrow Transplant 38 433 436 1:CAS:528: DC%2BD28XovF2ksL8%3D 10.1038/sj.bmt.1705463 16892074
34. SH Lim Y Zhang Z Wang WV Esler D Beggs B Pruitt, et al. 2005 Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia Bone Marrow Transplant 35 207 208 1:CAS:528:DC%2BD28XhtFCrtbbM 10.1038/sj.bmt.1704742 15531902
35. EB Kim DS Kim SJ Park Y Park KH Rho SJ Kim 2008 Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy Cancer Res Treat 40 36 38 10.4143/crt.2008.40. 1.36 19688064
36. H Sakamaki Y Sato SI Mori K Ohashi S Tanikawa H Akiyama, et al. 2001 Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation Int J Hematol 74 342 346 1:STN:280:DC%2BD3Mnns1WksQ%3D%3D 10.1007/BF02982072 11721974
37. K Matsue T Aoki J Odawara H Fujiwara K Iwama S Kimura, et al. 2009 High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients Eur J Haematol 83 357 364 1:CAS:528:DC%2BD1MXht1Oit7%2FI 10.1111/j.1600-0609.2009.01291.x 19508685
38. K Oshima M Sato S Okuda K Terasako H Nakasone S Kako, et al. 2009 Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease Hematology 14 73 75 1:CAS:528:DC%2BD1MXltlyhsb0%3D 10.1179/102453309X385223 19298717
39. W Yeo PJ Johnson 2006 Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy Hepatology 43 209 220 1:CAS:528:DC%2BD28XhvVSgu7o%3D 10.1002/hep.21051 16440366
40. T Umemura K Kiyosawa 2006 Fatal HBV reactivation in a subject with anti-HBs and anti-HBc Intern Med 45 747 748 10.2169/internalmedicine.45.0158 16847362
41. AS Lok RH Liang EK Chiu KL Wong TK Chan D Todd 1991 Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 182 188 1:STN:280: DyaK3M%2FmtVSiuw%3D%3D 1983820
42. W Yeo PK Chan WM Ho B Zee KC Lam KI Lei, et al. 2004 Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy J Clin Oncol 22 927 934 1:CAS:528:DC%2BD2cXpsVKisrg%3D 10.1200/JCO.2004.05.161 14990649
43. GK Lau HH Yiu DY Fong HC Cheng WY Au LS Lai, et al. 2003 Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy Gastroenterology 125 1742 1749 1:CAS:528: DC%2BD2cXhtVOruw%3D%3D 10.1053/j.gastro.2003.09.026 14724827
44. SN Pei CH Chen CM Lee MC Wang MC Ma TH Hu, et al. 2010 Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients Ann Hematol 89 255 262 1:CAS:528:DC%2BC3cXpsVSiug%3D%3D 10.1007/s00277-009-0806-7 19697028
45. N Fukushima T Mizuta M Tanaka M Yokoo M Ide T Hisatomi, et al. 2009 Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier Ann Oncol 20 2013 2017 1:STN:280:DC%2BD1MjntFKlug%3D%3D 10.1093/annonc/mdp230 19561036
46. MM Hassan D Li AS El-Deeb RA Wolff ML Bondy M Davila, et al. 2008 Association between hepatitis B virus and pancreatic cancer J Clin Oncol 26 4557 4562 10.1200/JCO.2008.17.3526 18824707
47. C Targhetta MG Cabras AM Mamusa G Mascia E Angelucci 2008 Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy Haematologica 93 951 952 10.3324/haematol.12557 18515881
48. D Francisci F Falcinelli E Schiaroli M Capponi B Belfiori L Flenghi, et al. 2010 Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy Infection 38 58 61 1:STN:280:DC%2BC3c7itVWjtg%3D%3D 10.1007/s15010-009-9019-1 19904491
49. D Bedognetti G Zoppoli MR Sertoli E Zanardi P Blandini L Uccellini, et al. 2010 Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era Int J Hematol 91 342 344 10.1007/s12185-010-0522-z 20191334 (author reply 5-6)
50. YX Koo DS Tan IB Tan M Tao WC Chow ST Lim 2010 Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy Cancer 116 115 121 1:CAS:528:DC%2BC3cXitFGitbs%3D 19899164
51. D Ji J Cao X Hong J Li J Wang F Chen, et al. 2010 Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study Eur J Haematol 85 243 250 1:CAS:528:DC%2BC3cXhtFKjsL3P 10.1111/j.1600-0609.2010.01474.x 20491883
52. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 661 662 10.1002/hep.23190 19714720
53. H Tsubouchi H Kumada K Kiyosawa S Mochida I Sakaida E Tanaka, et al. 2009 Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis Kanzo 50 38 42 10.2957/kanzo.50.38
54. CM Weinbaum I Williams EE Mast SA Wang L Finelli A Wasley, et al. 2008 Recommendations for identification and public health management of persons with chronic hepatitis B virus infection MMWR Recomm Rep 57 1 20 18802412
55. Ide Y, Ito Y, Takahashi S, Tokudome N, Kobayashi K, Sugihara T, et al. Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer. Breast Cancer 2010. doi: 10.1007/s12282-010-0213-x.
56. T Matsumoto H Marusawa M Dogaki Y Suginoshita T Inokuma 2010 Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection Liver Int 30 1241 1242 10.1111/j.1478-3231.2010.02238.x 20345703